Cellectis S.A. (NASDAQ:CLLS) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET
Company Participants
Arthur Stril - Chief Business Officer
Andre Choulika - Chief Executive Officer
Bing Wang - Chief Financial Officer
Mark Frattini - Chief Medical Officer
Conference Call Participants
Dev Prasad - Jefferies
Gena Wang - Barclays
Andrea Tan - Goldman Sachs
Jack Allen - Baird
Hartaj Singh - Oppenheimer & Company
David Dai - SMBC
Yanan Zhu - Wells Fargo Securities
Brooke Schuster - William Blair
Silvan Tuerkcan - JMP Securities
Operator
Good morning, everyone and welcome to Cellectis Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] Please be aware that today’s conference call is being recorded. I’d now like to introduce you the first speaker, Arthur Stril, Chief Business Officer. You may begin.
Arthur Stril
Good morning and welcome everyone to Cellectis fourth quarter and full year 2022 corporate update and financial results conference call. Joining me on the call today with prepared remarks are Dr. Andre Choulika, our Chief Executive Officer; Dr. Bing Wang, our Chief Financial Officer; and Dr. Mark Frattini, our Chief Medical Officer. Yesterday evening, Cellectis issued a press release reporting its financial results for the fourth quarter and full year 2022 ended December 31, 2022. The press release is available on our website at cellectis.com. We expect to file the annual reports in the coming days.
As a reminder, we will make statements regarding Cellectis’ financial outlook in addition to its manufacturing, regulatory and product development status and plans and product development of its license partners. These forward statements, which are based on our management’s current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the Securities and Exchange Commission, SEC and the financial reports, including the management report for the year ended on December 31, 2021 and subsequent filings Cellectis makes with the SEC from time-to-time.
I would now like to turn the call over to Andre.
Andre Choulika
Thank you, Arthur. Good morning and thank you everyone for joining us today. 2022 has been a milestone year for Cellectis. We have reached key milestones for our clinical trials that we are thrilled to share with you today. In December 2022, Cellectis presented positive preliminary clinical data from 5 additional patients from our BALLI-01 trial evaluating UCART22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia or ALL. In this Phase 1/2a study, the 5 additional patients received UCART22 at dose level 3 after lymphodepletion with fludarabine, cyclophosphamide and alemtuzumab, or FCA preconditioning regimen. These results showed evidence of UCART22 anti-tumor activity observed in 3 of the 5 or 60% of the patients. Overall, these preliminary data support the continued administration of UCART22 after FCA linked to depletion in patients with relapsed or refractory B-cell ALL.